Novartis, developer of the brand-name Lucentis, announced on Friday that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has granted the drug a positive opinion for the treatment of retinopathy of prematurity in infants.
Biosimilars of ranibizumab (Lucentis) are on the horizon, with developers including Xbrane, Coherus BioSciences, and Samsung Bioepis all advancing proposed biosimilars referencing the anti—vascular endothelial growth factor (anti-VEGF) therapy. However, ahead of facing competition, the eye drug could gain a new European indication.
Novartis, developer of the brand-name Lucentis, announced on Friday that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has granted the drug a positive opinion for the treatment of retinopathy of prematurity (ROP) in infants. ROP is a rare eye disease that is the leading cause of childhood blindness. ROP affects premature infants and is caused by the abnormal development of retinal blood vessels spurred by high levels of VEGF.
If ranibizumab is approved in this indication, it will be the first time that a drug has been approved for this patient population.
The CHMP opinion relied on data from the RAINBOW clinical study, which was conducted among 224 participants at 87 sites worldwide. Patients with ROP were randomized to receive 1 of 3 therapies: 0.2 mg of ranibizumab injected on day 1 and up to 2 retreatments for each eye, 0.1 mg of ranibizumab on day 1 and up to 2 retreatments per eye, or laser therapy.
The primary outcome measure was the percentage of patients with an absence of active ROP and an absence of unfavorable structural outcomes in both eyes at week 24. In total, 80% of patients who received 0.2 mg of ranibizumab and 75% of those who received 0.1 mg of ranibizumab achieved this outcome versus 66.2% of patients who received laser therapy. Adverse events were reported in 35.62%, 31.58%, and 34.78% of patients in the 3 groups, respectively.
“Given this vulnerable patient population, and the limitations of current treatments, randomized controlled clinical studies are important to ensure safe and effective use of pharmacological therapies in pediatric patient populations. If approved, ranibizumab will be a valuable alternative treatment option to laser therapy,” commented Andreas Stahl, MD, director of the department of ophthalmology, University Medical Center Greifswald, in a statement announcing the CHMP opinion.
Novartis indicated that it expects to receive the European Commission’s decision on the drug within the next 3 months.
BioRationality: MHRA's Procedure Enables Automatic Registration of Biosimilars Approved Elsewhere
March 18th 2024Sarfaraz K. Niazi, PhD, explains how the new international recognition procedure under the Medicines and Healthcare Products Regulatory Agency (MHRA) could expand biosimilar access within the United Kingdom, in his latest column.
A New Chapter: How 2023 Will Shape the US Biosimilar Space for 2024 and Beyond
December 31st 2023On this episode of Not So Different, Cencora's Brian Biehn and Corey Ford take a look back at major policy and regulatory advancements in 2023 and how these changes will alter the space going forward.
Coherus Biosciences Cites Biosimilars as Main Drivers of 2023 Revenue Growth
March 14th 2024In its earnings report for the fourth quarter and full year of 2023, Coherus Biosciences detailed its rising revenue growth, which it partly attributed to increased sales for its pegfilgrastim and ranibizumab biosimilars.
The Subcutaneous Revolution: Zymfentra and the Future of IBD Care With Dr Andres Yarur
December 17th 2023On this episode of Not So Different, Andres Yarur, MD, a researcher and associate professor of medicine at Cedars-Sinai Medical Center, discusses the significance of the FDA approval for Zymfentra, the world's first subcutaneous infliximab product, for patients with inflammatory bowel disease (IBD).
Eye on Pharma: Canadian Aflibercept Settlement; Sandoz Acquires Cimerli; Payer Chooses Cyltezo
March 6th 2024Biocon Biologics settled with the maker of Eylea (aflibercept), announcing a launch date for its biosimilar competitor in Canada; Sandoz has officially acquired Cimerli, a ranibizumab biosimilar; AARP Medicare Rx from United Healthcare has added Cyltezo (adalimumab-adbm) and removed the originator (Humira) from its formulary.